Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxideSimon Couillard, Ian Pavord, Annette Laugerud et al.|Thorax|2021Cited by 169
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialSanjay Ramakrishnan, Mona Bafadhel, Hafiz Taha Mahmood et al.|The Lancet Respiratory Medicine|2024Cited by 98
Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)Imran Howell, Ian Pavord, Mahdi Mahdi et al.|JMIR Research Protocols|2023Cited by 9
Fractional exhaled nitric oxide and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational studyImran Howell, Ian Pavord, Mona Bafadhel et al.|European Respiratory Journal|2025Cited by 5